Loss of neurofibromin Ras-GAP activity enhances the formation of cardiac blood islands in murine embryos

  1. Amanda D Yzaguirre
  2. Arun Padmanabhan
  3. Eric D de Groh
  4. Kurt A Engleka
  5. Jun Li
  6. Nancy A Speck
  7. Jonathan A Epstein  Is a corresponding author
  1. University of Pennsylvania, United States
  2. Harvard Medical School, United States
  3. Medpace Inc., United States

Abstract

Type I Neurofibromatosis (NF1) is caused by mutations in the NF1 gene encoding neurofibromin. Neurofibromin exhibits Ras GTPase activating protein (Ras-GAP) activity that is thought to mediate cellular functions relevant to disease phenotypes. Loss of murine Nf1 results in embryonic lethality due to heart defects, while mice with monoallelic loss of function mutations, or with tissue-specific inactivation have been used to model NF1. Here, we characterize previously unappreciated phenotypes in Nf1-/- embryos, which are inhibition of hemogenic endothelial specification in the dorsal aorta, enhanced yolk sac hematopoiesis, and exuberant cardiac blood island formation. We show that a missense mutation engineered into the active site of the Ras-GAP domain is sufficient to reproduce ectopic blood island formation, cardiac defects and overgrowth of neural crest-derived structures seen in Nf1-/- embryos. These findings demonstrate a role for Ras-GAP activity in suppressing hemogenic potential of the heart, and restricting growth of neural crest-derived tissues.

Article and author information

Author details

  1. Amanda D Yzaguirre

    Abramson Family Cancer Research Institute, Department of Cell and Developmental Biology, Institute for Regenerative Medicine, Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Arun Padmanabhan

    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Eric D de Groh

    Medpace Inc., Cincinnati, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Kurt A Engleka

    Cardiovascular Institute, Department of Cell and Developmental Biology, Institute for Regenerative Medicine, Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Jun Li

    Cardiovascular Institute, Department of Cell and Developmental Biology, Institute for Regenerative Medicine, Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Nancy A Speck

    Abramson Family Cancer Research Institute, Department of Cell and Developmental Biology, Institute for Regenerative Medicine, Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Jonathan A Epstein

    Cardiovascular Institute, Department of Cell and Developmental Biology, Institute for Regenerative Medicine, Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania, Philadelphia, United States
    For correspondence
    epsteinj@upenn.edu
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Kevin Shannon, University of California, San Francisco, United States

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations inthe Guide for the Care and Use of Laboratory Animals of the NationalInstitutes of Health. All of the animals were handled according toapproved institutional animal care and use committee (IACUC) protocols(#803789 and #803317) of the University of Pennsylvania.

Version history

  1. Received: March 30, 2015
  2. Accepted: October 12, 2015
  3. Accepted Manuscript published: October 13, 2015 (version 1)
  4. Version of Record published: December 8, 2015 (version 2)

Copyright

© 2015, Yzaguirre et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,006
    views
  • 349
    downloads
  • 14
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Amanda D Yzaguirre
  2. Arun Padmanabhan
  3. Eric D de Groh
  4. Kurt A Engleka
  5. Jun Li
  6. Nancy A Speck
  7. Jonathan A Epstein
(2015)
Loss of neurofibromin Ras-GAP activity enhances the formation of cardiac blood islands in murine embryos
eLife 4:e07780.
https://doi.org/10.7554/eLife.07780

Share this article

https://doi.org/10.7554/eLife.07780

Further reading

    1. Cell Biology
    Joanne Tung, Lei Huang ... Adriana Ordonez
    Research Article

    Activating transcription factor 6 (ATF6) is one of three endoplasmic reticulum (ER) transmembrane stress sensors that mediate the unfolded protein response (UPR). Despite its crucial role in long-term ER stress adaptation, regulation of ATF6 alpha (α) signalling remains poorly understood, possibly because its activation involves ER-to-Golgi and nuclear trafficking. Here, we generated an ATF6α/Inositol-requiring kinase 1 (IRE1) dual UPR reporter CHO-K1 cell line and performed an unbiased genome-wide CRISPR/Cas9 mutagenesis screen to systematically profile genetic factors that specifically contribute to ATF6α signalling in the presence and absence of ER stress. The screen identified both anticipated and new candidate genes that regulate ATF6α activation. Among these, calreticulin (CRT), a key ER luminal chaperone, selectively repressed ATF6α signalling: Cells lacking CRT constitutively activated a BiP::sfGFP ATF6α-dependent reporter, had higher BiP levels and an increased rate of trafficking and processing of ATF6α. Purified CRT interacted with the luminal domain of ATF6α in vitro and the two proteins co-immunoprecipitated from cell lysates. CRT depletion exposed a negative feedback loop implicating ATF6α in repressing IRE1 activity basally and overexpression of CRT reversed this repression. Our findings indicate that CRT, beyond its known role as a chaperone, also serves as an ER repressor of ATF6α to selectively regulate one arm of the UPR.

    1. Cancer Biology
    2. Cell Biology
    Alex Weiss, Cassandra D'Amata ... Madeline N Hayes
    Research Article

    High-throughput vertebrate animal model systems for the study of patient-specific biology and new therapeutic approaches for aggressive brain tumors are currently lacking, and new approaches are urgently needed. Therefore, to build a patient-relevant in vivo model of human glioblastoma, we expressed common oncogenic variants including activated human EGFRvIII and PI3KCAH1047R under the control of the radial glial-specific promoter her4.1 in syngeneic tp53 loss-of-function mutant zebrafish. Robust tumor formation was observed prior to 45 days of life, and tumors had a gene expression signature similar to human glioblastoma of the mesenchymal subtype, with a strong inflammatory component. Within early stage tumor lesions, and in an in vivo and endogenous tumor microenvironment, we visualized infiltration of phagocytic cells, as well as internalization of tumor cells by mpeg1.1:EGFP+ microglia/macrophages, suggesting negative regulatory pressure by pro-inflammatory cell types on tumor growth at early stages of glioblastoma initiation. Furthermore, CRISPR/Cas9-mediated gene targeting of master inflammatory transcription factors irf7 or irf8 led to increased tumor formation in the primary context, while suppression of phagocyte activity led to enhanced tumor cell engraftment following transplantation into otherwise immune-competent zebrafish hosts. Altogether, we developed a genetically relevant model of aggressive human glioblastoma and harnessed the unique advantages of zebrafish including live imaging, high-throughput genetic and chemical manipulations to highlight important tumor-suppressive roles for the innate immune system on glioblastoma initiation, with important future opportunities for therapeutic discovery and optimizations.